ANDA 202830, held by Amneal Pharmaceuticals. Lisdexamfetamine Dimesylate.
As of Nov 21, 2026, ANDA 202830 (Lisdexamfetamine Dimesylate), held by Amneal Pharmaceuticals, was first approved by FDA on Aug 25, 2023, with 1 approved supplement and 0 published complete response letters.
Lisdexamfetamine dimesylate capsules are indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older Moderate to severe binge eating disorder (BED) in adults. Limitations of Use: Pediatric patients with ADHD younger than 6 years of age experienced more long-term weight loss than patients 6 years and older. Lisdexamfetamine dimesylate capsules are not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 25, 2023 | Original application | Approved | None posted |
| Lisdexamfetamine Dimesylate20MG · capsule;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate30MG · capsule;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate40MG · capsule;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate50MG · capsule;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate60MG · capsule;oral | Lisdexamfetamine Dimesylate | Rx |
| Lisdexamfetamine Dimesylate70MG · capsule;oral | Lisdexamfetamine Dimesylate | Rx |
| Sep 16, 2024 | Supplement 2Labeling · Standard review | Approved | None posted |
| Aug 25, 2023 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters